{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:30:50Z","timestamp":1793298650802,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,4]]},"DOI":"10.7759\/cureus.89355","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T18:18:50Z","timestamp":1754331530000},"source":"Crossref","is-referenced-by-count":1,"title":["Evidence From a Systematic Review of Non-alcoholic Fatty Liver Disease (NAFLD)\/Metabolic Dysfunction-Associated Fatty Liver Disease (MASLD) Fueling Cardiovascular Risk"],"prefix":"10.7759","author":[{"given":"Nehal K","family":"Bhatt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashasvi","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanathanan","family":"Neelakantan Ramaswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manvitha","family":"Bendagiri Matam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samyuktha","family":"Harikrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalvin","family":"Chand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hetavi","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iana","family":"Malasevskaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella ME","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al.. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023, 78:1966-86. 10.1097\/HEP.0000000000000520","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.08.038","article-title":"Serum biomarkers are associated with atherosclerotic cardiovascular disease among patients with nonalcoholic fatty liver disease undergoing elective angiography","volume":"20","author":"Younossi ZM","year":"2022","unstructured":"Younossi ZM, Felix S, Jeffers T, et al.. Serum biomarkers are associated with atherosclerotic cardiovascular disease among patients with nonalcoholic fatty liver disease undergoing elective angiography. Clin Gastroenterol Hepatol. 2022, 20:e1149-56. 10.1016\/j.cgh.2021.08.038","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-2247","article-title":"Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients","volume":"30","author":"Targher G","year":"2007","unstructured":"Targher G, Bertolini L, Padovani R, et al.. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007, 30:1212-8. 10.2337\/dc06-2247","journal-title":"Diabetes Care"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01220-x","article-title":"Metabolic syndrome, fatty liver, and artificial intelligence-based epicardial adipose tissue measures predict long-term risk of cardiac events: a prospective study","volume":"20","author":"Lin A","year":"2021","unstructured":"Lin A, Wong ND, Razipour A, et al.. Metabolic syndrome, fatty liver, and artificial intelligence-based epicardial adipose tissue measures predict long-term risk of cardiac events: a prospective study. Cardiovasc Diabetol. 2021, 20:27. 10.1186\/s12933-021-01220-x","journal-title":"Cardiovasc Diabetol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.12.026","article-title":"Nonalcoholic fatty liver disease and fibrosis associated\u00a0with increased risk of cardiovascular events\u00a0in\u00a0a\u00a0prospective study","volume":"18","author":"Baratta F","year":"2020","unstructured":"Baratta F, Pastori D, Angelico F, et al.. Nonalcoholic fatty liver disease and fibrosis associated\u00a0with increased risk of cardiovascular events\u00a0in\u00a0a\u00a0prospective study. Clin Gastroenterol Hepatol. 2020, 18:2324-2331.e4. 10.1016\/j.cgh.2019.12.026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.07.030","article-title":"Association of hepatic steatosis with major adverse cardiovascular events, independent of coronary artery disease","volume":"19","author":"Meyersohn NM","year":"2021","unstructured":"Meyersohn NM, Mayrhofer T, Corey KE, et al.. Association of hepatic steatosis with major adverse cardiovascular events, independent of coronary artery disease. Clin Gastroenterol Hepatol. 2021, 19:1480-1488.e14. 10.1016\/j.cgh.2020.07.030","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16086","article-title":"Metabolic syndrome traits differentially and cumulatively influence micro- and macrovascular disease risk in patients with MASLD","volume":"44","author":"Henney AE","year":"2024","unstructured":"Henney AE, Riley DR, Hydes TJ, et al.. Metabolic syndrome traits differentially and cumulatively influence micro- and macrovascular disease risk in patients with MASLD. Liver Int. 2024, 44:3031-49. 10.1111\/liv.16086","journal-title":"Liver Int"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000286","article-title":"The association between hepatic steatosis and incident cardiovascular disease, cancer, and all-cause mortality in a US multicohort study","volume":"77","author":"Ahmed HS","year":"2023","unstructured":"Ahmed HS, Wang N, Carr JJ, et al.. The association between hepatic steatosis and incident cardiovascular disease, cancer, and all-cause mortality in a US multicohort study. Hepatology. 2023, 77:2063-72. 10.1097\/HEP.0000000000000286","journal-title":"Hepatology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.11.026","article-title":"Nonalcoholic fatty liver disease associates with increased overall mortality and death from cancer, cardiovascular disease, and liver disease in women but not men","volume":"16","author":"Hwang YC","year":"2018","unstructured":"Hwang YC, Ahn HY, Park SW, Park CY. Nonalcoholic fatty liver disease associates with increased overall mortality and death from cancer, cardiovascular disease, and liver disease in women but not men. Clin Gastroenterol Hepatol. 2018, 16:1131-1137.e5. 10.1016\/j.cgh.2017.11.026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2023.03.003","article-title":"Sex differences in cardiovascular and all-cause mortality in nonalcoholic fatty liver disease in the US population","volume":"33","author":"Ren R","year":"2023","unstructured":"Ren R, Zheng Y. Sex differences in cardiovascular and all-cause mortality in nonalcoholic fatty liver disease in the US population. Nutr Metab Cardiovasc Dis. 2023, 33:1349-57. 10.1016\/j.numecd.2023.03.003","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28253","article-title":"Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: a prospective cohort study","volume":"63","author":"Wong VW","year":"2016","unstructured":"Wong VW, Wong GL, Yeung JC, et al.. Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: a prospective cohort study. Hepatology. 2016, 63:754-63. 10.1002\/hep.28253","journal-title":"Hepatology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2025.104024","article-title":"Comparative association of MAFLD\/MASLD and subtypes with cardiovascular diseases outcomes","volume":"35","author":"Jin H","year":"2025","unstructured":"Jin H, Liang Z, Hu X, et al.. Comparative association of MAFLD\/MASLD and subtypes with cardiovascular diseases outcomes. Nutr Metab Cardiovasc Dis. 2025, 35:104024. 10.1016\/j.numecd.2025.104024","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2011.25554","article-title":"Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study","volume":"7","author":"Athyros VG","year":"2011","unstructured":"Athyros VG, Giouleme O, Ganotakis ES, et al.. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci. 2011, 7:796-805. 10.5114\/aoms.2011.25554","journal-title":"Arch Med Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani M","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016, 5:210. 10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"ref16","unstructured":"Newcastle-Ottawa Quality Assessment Form for Cohort Studies. (2017). Accessed. June 5, 2025: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK115843\/bin\/appe-fm3.pdf."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins JP","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al.. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011, 343:d5928. 10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.05.029","article-title":"Differential clinical characteristics and mortality outcomes in persons with NAFLD and\/or MAFLD","volume":"19","author":"Nguyen VH","year":"2021","unstructured":"Nguyen VH, Le MH, Cheung RC, Nguyen MH. Differential clinical characteristics and mortality outcomes in persons with NAFLD and\/or MAFLD. Clin Gastroenterol Hepatol. 2021, 19:2172-2181.e6. 10.1016\/j.cgh.2021.05.029","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2024.103798","article-title":"MAFLD as a predictor of adverse cardiovascular events among CHD patients with LDL-C<1.8\u00a0mmol\/L","volume":"35","author":"Song J","year":"2025","unstructured":"Song J, Liu Y, Liu Y, et al.. MAFLD as a predictor of adverse cardiovascular events among CHD patients with LDL-C&lt;1.8\u00a0mmol\/L. Nutr Metab Cardiovasc Dis. 2025, 35:103798. 10.1016\/j.numecd.2024.103798","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2024.06.001","article-title":"Associations of serum carotenoids with all-cause and cardiovascular mortality in adults with MAFLD","volume":"34","author":"Lin B","year":"2024","unstructured":"Lin B, Liu Z, Li D, Zhang T, Yu C. Associations of serum carotenoids with all-cause and cardiovascular mortality in adults with MAFLD. Nutr Metab Cardiovasc Dis. 2024, 34:2315-24. 10.1016\/j.numecd.2024.06.001","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.12.039","article-title":"Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population","volume":"10","author":"Stepanova M","year":"2012","unstructured":"Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol. 2012, 10:646-50. 10.1016\/j.cgh.2011.12.039","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.07.035","article-title":"Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States","volume":"75","author":"Kim D","year":"2021","unstructured":"Kim D, Konyn P, Sandhu KK, Dennis BB, Cheung AC, Ahmed A. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol. 2021, 75:1284-91. 10.1016\/j.jhep.2021.07.035","journal-title":"J Hepatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.12.022","article-title":"Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study","volume":"19","author":"Lee H","year":"2021","unstructured":"Lee H, Lee YH, Kim SU, Kim HC. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study. Clin Gastroenterol Hepatol. 2021, 19:2138-2147.e10. 10.1016\/j.cgh.2020.12.022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2024.10.019","article-title":"Association between systemic inflammation markers and cardiovascular mortality in adults with metabolic dysfunction-associated steatotic liver disease","volume":"35","author":"Zhang Z","year":"2025","unstructured":"Zhang Z, Zhang W, Liu Z, Ou J, Sun Y, Zhang L, Ji G. Association between systemic inflammation markers and cardiovascular mortality in adults with metabolic dysfunction-associated steatotic liver disease. Nutr Metab Cardiovasc Dis. 2025, 35:103781. 10.1016\/j.numecd.2024.10.019","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2023.01.013","article-title":"Comparison of cardiovascular mortality between MAFLD and NAFLD: a cohort study","volume":"33","author":"Yoo TK","year":"2023","unstructured":"Yoo TK, Lee MY, Kim SH, Zheng MH, Targher G, Byrne CD, Sung KC. Comparison of cardiovascular mortality between MAFLD and NAFLD: a cohort study. Nutr Metab Cardiovasc Dis. 2023, 33:947-55. 10.1016\/j.numecd.2023.01.013","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.02.045","article-title":"Hepatic steatosis and cardiovascular disease outcomes: an analysis of the Framingham Heart Study","volume":"63","author":"Mellinger JL","year":"2015","unstructured":"Mellinger JL, Pencina KM, Massaro JM, et al.. Hepatic steatosis and cardiovascular disease outcomes: an analysis of the Framingham Heart Study. J Hepatol. 2015, 63:470-6. 10.1016\/j.jhep.2015.02.045","journal-title":"J Hepatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis","volume":"6","author":"Mantovani A","year":"2021","unstructured":"Mantovani A, Csermely A, Petracca G, et al.. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021, 6:903-13. 10.1016\/S2468-1253(21)00308-3","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2023.08.013","article-title":"The independent association of non-alcoholic fatty liver disease with incident cardiovascular disease: a GRADE evaluation of the evidence through a systematic review and meta-analysis","volume":"14","author":"Prasad M","year":"2024","unstructured":"Prasad M, Gupta S, Sarin SK. The independent association of non-alcoholic fatty liver disease with incident cardiovascular disease: a GRADE evaluation of the evidence through a systematic review and meta-analysis. J Clin Exp Hepatol. 2024, 14:101277. 10.1016\/j.jceh.2023.08.013","journal-title":"J Clin Exp Hepatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.101643","article-title":"Cardiovascular morbidity and mortality related to non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"48","author":"Bisaccia G","year":"2023","unstructured":"Bisaccia G, Ricci F, Khanji MY, et al.. Cardiovascular morbidity and mortality related to non-alcoholic fatty liver disease: a systematic review and meta-analysis. Curr Probl Cardiol. 2023, 48:101643. 10.1016\/j.cpcardiol.2023.101643","journal-title":"Curr Probl Cardiol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2023.102938","article-title":"Association between non-alcoholic fatty liver disease and coronary artery disease outcomes: a systematic review and meta-analysis","volume":"18","author":"Abosheaishaa H","year":"2024","unstructured":"Abosheaishaa H, Hussein M, Ghallab M, et al.. Association between non-alcoholic fatty liver disease and coronary artery disease outcomes: a systematic review and meta-analysis. Diabetes Metab Syndr. 2024, 18:102938. 10.1016\/j.dsx.2023.102938","journal-title":"Diabetes Metab Syndr"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/394633-evidence-from-a-systematic-review-of-non-alcoholic-fatty-liver-disease-nafldmetabolic-dysfunction-associated-fatty-liver-disease-masld-fueling-cardiovascular-risk","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T18:18:51Z","timestamp":1754331531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/394633-evidence-from-a-systematic-review-of-non-alcoholic-fatty-liver-disease-nafldmetabolic-dysfunction-associated-fatty-liver-disease-masld-fueling-cardiovascular-risk"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.89355","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,4]]}}}